Ventyx Biosciences, Sanofi
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need,
GlobalData on MSN9h
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m dealUnder the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
Sanofi SA (NASDAQ:SNY) agreed to make a $27 million strategic investment in Ventyx Biosciences Inc (NASDAQ:VTYX). “We look ...
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report).
Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...
Ventyx Biosciences Inc (VTYX) stock saw a decline, ending the day at $2.3 which represents a decrease of $-0.07 or -2.95% from the prior close of $2.37. The stock opened at $2.34 and touched a low of ...
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...
It's another big week on Wall Street. The major indexes (^DJI,^GSPC, ^IXIC) are set to open higher, looking to build on last week's big gains. A number of Federal Reserve officials will speak about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback